Evidence map›Paper›PMID 36549555›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2023

Development of a porous layer-by-layer microsphere with branched aliphatic hydrocarbon porogens.

Farah Shahjin, Milankumar Patel, Mahmudul Hasan, Jacob D Cohen, Farhana Islam, Md Ashaduzzaman, Mohammad Ullah Nayan, Mahadevan Subramaniam, You Zhou, Irene Andreu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Farah ShahjinDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA.
Milankumar PatelDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA.
Mahmudul HasanDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.
Jacob D CohenDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA.
Farhana IslamDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
Md AshaduzzamanComputer Science, University of Nebraska-Omaha, Omaha, NE, USA.
Mohammad Ullah NayanDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA.
Mahadevan SubramaniamComputer Science, University of Nebraska-Omaha, Omaha, NE, USA.
You ZhouCenter for Biotechnology, University of Nebraska-Lincoln, Lincoln, NE, USA.
Irene AndreuDepartment of Chemical Engineering, University of Rhode Island, Kingston, RI, USA.
Howard E GendelmanDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA. Electronic address: hegendel@unmc.edu.
Bhavesh D KevadiyaDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA.

Funding

Targeted mass spectrometry approaches to understand CART processing and recepter interactionsP20GM113126 · NIGMS · UNIVERSITY OF NEBRASKA LINCOLN · PI GUO, JIANTAO · 2016 to 2025
$20.8M
Pharmacokinetics and Drug-Drug InteractionsP01DA028555 · NIDA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BOSKA, MICHAEL DOUGLAS · 2010 to 2019
$16.8M
Neuroprotective Immunity and HIV DementiaR01NS034239 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Howard E Gendelman, R Lee Mosley · 1995 to 2026
$12.3M
Proteomics CoreP01NS043985 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI IKEZU, TSUNEYA · 2003 to 2012
$11.8M
Nanomedicine and NeuroAIDSR01NS036126 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 1997 to 2017
$5.7M
Prodrug Formulations Create Sustained-Release AntiretroviralsR01AI145542 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Benson Edagwa, Howard E Gendelman · 2019 to 2026
$5.3M
Targeted lipid nanoparticles for gene therapeutics delivery approach to eradicating HIV reservoirsR01MH121402 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Benson Edagwa, Howard E Gendelman · 2019 to 2026
$4.9M
Combined Molecular Excision Therapy (CMET) for Eliminating HIV-1R01MH115860 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 2017 to 2021
$3.5M
LASER ART for PrePR01AI158160 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI EDAGWA, BENSON, GENDELMAN, HOWARD E · 2021 to 2025
$3.5M
HIV-1DetectionandEliminationFrom CNS Mononuclear PhagocytesR01NS126089 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E, GORANTLA, SANTHI · 2021 to 2025
$3.5M
Anesthetic activation of TASK-3 tandem pore potassium channels: molecular mechanisms and behavioral effectsR01GM128009 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI COTTEN, JOSEPH F · 2018 to 2021
$1.6M
Neuroimmunology of Disease Training ProgramT32NS105594 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Aditya N Bade, Howard E Gendelman · 2018 to 2026
$1.4M
NIAID NIH HHS R01 AI145542NIAID NIH HHS R01 AI158160NIDA NIH HHS P01 DA028555NIGMS NIH HHS P20 GM113126NIGMS NIH HHS R01 GM128009NIMH NIH HHS R01 MH115860NIMH NIH HHS R01 MH121402NINDS NIH HHS P01 NS043985NINDS NIH HHS R01 NS034239NINDS NIH HHS R01 NS036126NINDS NIH HHS R01 NS126089NINDS NIH HHS T32 NS105594
6 · The paper itself

Abstract

Porous polymer microspheres are employed in biotherapeutics, tissue engineering, and regenerative medicine. Porosity dictates cargo carriage and release that are aligned with the polymer physicochemical properties. These include material tuning, biodegradation, and cargo encapsulation. How uniformity of pore size affects therapeutic delivery remains an area of active investigation. Herein, we characterize six branched aliphatic hydrocarbon-based porogen(s) produced to create pores in single and multilayered microspheres. The porogens are composed of biocompatible polycaprolactone, poly(lactic-co-glycolic acid), and polylactic acid polymers within porous multilayered microspheres. These serve as controlled effective drug and vaccine delivery platforms.

Indexed as

Drug Delivery SystemsPolymersHydrocarbonsMicrospheresParticle SizePorosityHydrocarbonsPolymersLayer-by-layerPoly(glycolide-co-lactide)PolylactidePoly(ε-caprolactone)PorogensPorous microspheresSolvent evaporation

Identifiers

PMID36549555
PMCPMC10460474

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.